Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis
- PMID: 39821033
- DOI: 10.1007/978-3-031-70875-6_17
Metabolic Reprogramming and Adaption in Breast Cancer Progression and Metastasis
Abstract
Recent evidence has revealed that cancer is not solely driven by genetic abnormalities but also by significant metabolic dysregulation. Cancer cells exhibit altered metabolic demands and rewiring of cellular metabolism to sustain their malignant characteristics. Metabolic reprogramming has emerged as a hallmark of cancer, playing a complex role in breast cancer initiation, progression, and metastasis. The different molecular subtypes of breast cancer exhibit distinct metabolic genotypes and phenotypes, offering opportunities for subtype-specific therapeutic approaches. Cancer-associated metabolic phenotypes encompass dysregulated nutrient uptake, opportunistic nutrient acquisition strategies, altered utilization of glycolysis and TCA cycle intermediates, increased nitrogen demand, metabolite-driven gene regulation, and metabolic interactions with the microenvironment. The tumor microenvironment, consisting of stromal cells, immune cells, blood vessels, and extracellular matrix components, influences metabolic adaptations through modulating nutrient availability, oxygen levels, and signaling pathways. Metastasis, the process of cancer spread, involves intricate steps that present unique metabolic challenges at each stage. Successful metastasis requires cancer cells to navigate varying nutrient and oxygen availability, endure oxidative stress, and adapt their metabolic processes accordingly. The metabolic reprogramming observed in breast cancer is regulated by oncogenes, tumor suppressor genes, and signaling pathways that integrate cellular signaling with metabolic processes. Understanding the metabolic adaptations associated with metastasis holds promise for identifying therapeutic targets to disrupt the metastatic process and improve patient outcomes. This chapter explores the metabolic alterations linked to breast cancer metastasis and highlights the potential for targeted interventions in this context.
Keywords: Breast cancer; Circulating tumor cells (CTCs); Epithelial-mesenchymal transition (EMT); Metabolism; Metastasis; Metastatic colonization.
© 2025. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.Mol Cancer. 2024 Nov 21;23(1):261. doi: 10.1186/s12943-024-02165-x. Mol Cancer. 2024. PMID: 39574178 Free PMC article. Review.
-
Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers.Biomed Pharmacother. 2024 Dec;181:117714. doi: 10.1016/j.biopha.2024.117714. Epub 2024 Nov 29. Biomed Pharmacother. 2024. PMID: 39615165 Review.
-
Metabolic reprogramming in breast cancer results in distinct mitochondrial bioenergetics between luminal and basal subtypes.FEBS J. 2019 Feb;286(4):688-709. doi: 10.1111/febs.14756. Epub 2019 Feb 5. FEBS J. 2019. PMID: 30657636
-
Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with "Warburg-like" cancer metabolism and L-lactate production.Cell Cycle. 2012 Aug 15;11(16):3019-35. doi: 10.4161/cc.21384. Epub 2012 Aug 9. Cell Cycle. 2012. PMID: 22874531 Free PMC article.
-
Metastatic breast cancer cells are metabolically reprogrammed to maintain redox homeostasis during metastasis.Redox Biol. 2024 Sep;75:103276. doi: 10.1016/j.redox.2024.103276. Epub 2024 Jul 20. Redox Biol. 2024. PMID: 39053265 Free PMC article.
Cited by
-
CD2-CD58 axis orchestrates cytotoxic T lymphocyte function and metabolic crosstalk in breast cancer brain metastasis.J Cell Commun Signal. 2025 Aug 24;19(3):e70040. doi: 10.1002/ccs3.70040. eCollection 2025 Sep. J Cell Commun Signal. 2025. PMID: 40859981 Free PMC article.
References
-
- Abdelwahab MG et al (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One 7(5)
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical